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Protein oxidation has been linked to accelerated aging and is a
contributing factor tomanydiseases.Methionine residues are par-
ticularly susceptible to oxidation, but the resulting mixture of
methionine R-sulfoxide (Met-RO) and methionine S-sulfoxide
(Met-SO) can be repaired by thioredoxin-dependent enzymes
MsrB and MsrA, respectively. Here, we describe a knock-out
mouse deficient in selenoprotein MsrB1, the main mammalian
MsrB located in the cytosol and nucleus. In thesemice, in addition
to the deletion of 14-kDaMsrB1, a 5-kDa selenoprotein form was
specifically removed. Further studies revealed that the 5-kDa pro-
tein occurred inbothmouse tissues andhumanHEK293 cells; was
down-regulated by MsrB1 small interfering RNA, selenium defi-
ciency, and selenocysteine tRNAmutations; and was immunopre-
cipitated and recognized by MsrB1 antibodies. Specific labeling
with 75Se andmass spectrometry analyses revealed that the 5-kDa
selenoprotein corresponded to theC-terminal sequence ofMsrB1.
The MsrB1 knock-out mice lacked both 5- and 14-kDa MsrB1
forms and showed reducedMsrB activity, with the strongest effect
seen in liver and kidney. In addition, MsrA activity was decreased
by MsrB1 deficiency. Liver and kidney of the MsrB1 knock-out
micealsoshowed increased levelsofmalondialdehyde,proteincar-
bonyls, protein methionine sulfoxide, and oxidized glutathione as
well as reduced levels of free and protein thiols, whereas these
parameters were little changed in other organs examined. Overall,
this study established an important contribution of MsrB1 to the
redoxcontrol inmouse liverandkidneyand identifiedanovel form
of this protein.
Oxidation of proteins has been implicated in a variety of dis-
eases and is a factor that influences aging (1–3). Comparedwith
most other amino acids in proteins, Met is particularly suscep-
tible to oxidation by reactive oxygen species. The product of
such oxidation is a diastereomeric mixture of Met sulfoxides:
Met R-sulfoxide (Met-RO)2 and Met S-sulfoxide (Met-SO).
These oxidized forms, however, can be reduced back toMet by
two enzyme families, MsrA (specific for Met-SO) and MsrB
(specific for Met-RO) (4, 5).
Mammals contain one MsrA, which is targeted to different
cellular compartments by alternative splicing and variable use
of signal peptides (6, 7), and three MsrB isozymes, which are
individually targeted to different compartments (8–10). MsrB
located in the cytosol and nucleus is known as MsrB1 (also
designated as SelR or SelX). This protein is interesting in that it
is a selenoprotein that contains selenocysteine (Sec) in place of
cysteine normally present in the catalytic sites of MsrBs and
MsrAs (11). Dietary selenium is known to regulate the expres-
sion of selenoproteins and to ultimately control the redox
homeostasis in cells (12). Being a selenoprotein, the expression
of MsrB1 can also be regulated by dietary selenium (13–15).
Knock-out of the MsrA gene in mice was described several
years ago (16). The lack of MsrA results in the accumulation of
carbonyl derivatives (indicative of protein oxidation) (17),
increased susceptibility to exposure to 100% oxygen, and vari-
ous neurological abnormalities, such as tip-toe walking, abnor-
mal behavior, and lower locomotor activity (16, 18, 19). In addi-
tion, MsrB expression and activity were down-regulated in
these mice (13). Most interestingly, MsrA knock-out mice
showed a dramatically reduced life span (16), whereas overex-
pression of this protein in fruit flies increased their life span (20,
21). These studies are consistent with the idea that repair of
oxidized proteins is a critical factor in neurological diseases and
the aging process (4).
In contrast to MsrA, the consequence of MsrB deficiency in
mice or other animal models is not known (althoughMsrB also
can regulate the life span of yeast cells (22)). Selenium defi-
ciency was used to reduce MsrB1 expression (13, 16), which
resulted in lower MsrB activity as well as in a reduction in the
levels of other selenoproteins. This treatment increased protein
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oxidation and the amount of Met sulfoxide residues (13).
Whereas the knock-out of MsrA removed this protein in all
tissues and compartments, the specific removal of individual
MsrBs offers an opportunity to examine the effects of MsrB
deficiency in different organs, cells, and compartments.
In this work, we describe mice lacking MsrB1. We show that
MsrB1 knock-out led to protein oxidation and affected other
parameters indicative of oxidative stress. Most effects were
observed in the liver and kidney, where MsrB1 levels were par-
ticularly high, whereas several other organs were not affected.
An additional surprising finding was thatMsrB1 knock-out led
to the removal of a 5-kDa selenoprotein. We examined this
process in more detail and show that this protein corresponds
to the C-terminal segment of MsrB1.
EXPERIMENTAL PROCEDURES
Materials—General purpose chemicals were from Sigma,
DNA purification kits were fromQiagen, the RNA isolation kit
was from Ambion, and mammalian cell culture reagents and
protein electrophoresis reagents were from Invitrogen. Restric-
tion enzymes were from Fermentas. KODXLDNApolymerase
(Novagen) was used for genomic DNA amplification and for
MsrB1 knock-out allele screening.E. coliNovaBlue cells (Nova-
gen)were used for recombinantDNA transformation andBL21
(DE3) cells (Novagen) for recombinant protein synthesis.
MsrB1Knock-outMice—Two strategieswere used to prepare
MsrB1 knock-out (KO) mice. Two separate targeting con-
structs were prepared and used to target the MsrB1 gene by
homologous recombination (Fig. 1A). The following primer
pairs were used to amplify a 4550-bp region, upstream of the
first exon ofMsrB1 by nested PCR: UP_D1 5-TTCAGTGTT-
GGTGTAGGACTGTAGGAC-3, UP_D2 5-AGTCAGCGG-
CCGCCCTTACCAAGGTCATGAGTGACCAG-3, UP_R1
5-GCCTCCGAAGAAGCTGCAGAACGACAT-3, UP_R2
5-AGTAGCGGCCGCGGGAGCCGCTCCCAGGAAGCT-
TAG-3. The amplified fragment was cloned into the NotI site
of pPNT targeting vector, and the correct fragment orientation
was verified by restriction analysis and sequencing. This region
was common to both targeting constructs. The region down-
stream of the first exon of the MsrB1 gene was amplified by
nested PCRwith the following primer pairs (the first construct):
DWN_D1, 5-GTTATTGGGACTGGGTCGGGTTTGAG-
TCC-3; DWN_D2, 5-AGTCAGGATCCGGCCTTGAACT-
TCAAATGTAGATC-3; DWN_R1_1, 5-CGAATGCCTGA-
GGTTCTGACACTAACGTG-3; DWN_R2_1, 5-AGTCAG-
GTACCAGAGAGTGCTGTATGGTAAGTTCCAG-3. The
amplified 1080-bp fragment was cloned into BamHI-KpnI
sites of the pPNT targeting vector. For the second construct,
the following primer pairs were used: DWN_D1, 5-GTTA-
TTGGGACTGGGTCGGGTTTGAGTCC-3; DWN_D2, 5-
AGTCAGGATCCGGCCTTGAACTTCAAATGTAGATC-
3; DWN_R1_2, 5-CTTCGAGTGACTGGAGAACAGCTC-
ATAGC-3; DWN_R2_2, 5-AGTCAGGTACCGCCAGTGC-
TGCAGACACACAATACAG-3. The amplified 4824-bp
fragment was cloned into BamHI-KpnI sites of the pPNT tar-
geting vector.
More than 500 ES cell clones were tested for successful
MsrB1 targeting with these constructs; however, no positive
cells were detected, probably because of the high content of
repetitive elements in the vicinity of theMsrB1 gene (predicted
with RepeatMasker, available on the World Wide Web).
As an alternative strategy, amouse (in a 129/Sv genetic back-
ground) was generated at Texas Institute for Genomic Medi-
cine by taking advantage of the genetrap cassette inserted
immediately downstream of the MsrB1 gene (Fig. 1B).
Homozygous MsrB1 KO mice were obtained by mating het-
erozygous mice and selecting for homozygous MsrB1 KO by
genetic screening. Mice were handled following the guidelines
and approved protocols at the University of Nebraska-Lincoln.
Preparation of Protein Extracts fromMouse Tissues—Tissues
were glass-homogenized and sonicated in PBS, pH7.6, contain-
ing a mixture of protease inhibitors and 20 mM EDTA at 0 °C.
Metabolic Labeling of Mice and Cell Cultures with 75Se—
[75Se]Selenite (specific activity 1000 Ci/mmol) was obtained
from the Research Reactor Facility, University of Missouri
(Columbia, MO).Wild-type andMsrB1KOmice were injected
with 2.5 mCi of 75Se each and maintained for 2 days at a 12-h
light/dark cycle on a regular diet. The mice were sacrificed,
tissueswere extracted, and protein extractswere prepared from
various tissues in ice-cold PBS buffer, pH 7.6, supplemented
with complete protease inhibitor mixture from Roche Applied
Science. HEK 293 cells were grown and labeled with 75Se as
described (23). Extracts from the indicated mouse tissues or
human cells were subjected to SDS-PAGE, and proteins were
transferred onto polyvinylidene difluoride membranes and
analyzed with a PhosphorImager.
MsrB1 Knockdown—To down-regulate MsrB1 expression,
we used siRNA from Dharmacon. 4 l of siRNA in RNase-free
buffer were mixed with 1 l of DharmaFECT transfection rea-
gent and antibiotic-free/serum-free medium to a total volume
of 40 l. Samples were incubated for 30 min at room tempera-
ture and added to HEK 293 cells cultured in 6-well plates. After
24–48 h of incubation, mediumwas substituted with that con-
taining 75Se, and cells were incubated for an additional 12 h and
then washed with PBS, pH 7.6, and lysed with mammalian cell
lysis reagent from Sigma. The lysate was subjected to SDS-
PAGE electrophoresis and PhosphorImager analysis.
Dietary Studies—One-month-old BALB/c mice were main-
tained for 3 months on Torula yeast-based diets supplemented
with 0.1 ppm selenium or 0.4 ppm selenium (as sodium sele-
nite) or not supplemented with Se (0 ppm selenium) (Harlan
Teklad) as described (15). After 8 weeks, mice were sacrificed,
and protein extracts were prepared from the indicated tissues
and analyzed byWestern blot assayswith antibodies specific for
MsrB1, MsrA, MsrB2, MsrB3, or -actin.
Immunoprecipitation of MsrB1 Forms—MsrB1 antibodies
were added to protein extracts of mouse livers in PBS, pH 7.6,
containing complete protease inhibitor mixture. Samples were
further incubated at 4 °C with continuous shaking for 12 h.
MsrB1 was pooled using a Protein G immunoprecipitation kit
(Sigma) according to the manufacturer’s recommendations.
Affinity Enrichment of MsrB1 Forms—MsrB1 antibodies
were linked to activated BrCN-Sepharose from Sigma accord-
ing to the manufacturer’s recommendations. Total protein
extracts from30wild-typemouse livers in PBS, pH7.6, contain-
ing complete protease inhibitor mixture were incubated with
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the resin containing immobilized antibodies for 12 h at 4 °C.
The resinwas extensively washedwith 50mMTris-HCl, pH 8.0,
200 mM NaCl, to remove nonspecifically bound proteins.
MsrB1 forms were eluted with 3 ml of 0.1 M glycine, pH 2.5.
Proteins were reduced with 20 mM dithiothreitol for 30 min,
and cysteines/Sec were modified with 100 mM iodoacetamide
for 1 h at room temperature. Proteins were concentrated using
3 kDa cut-off Microcon concentrators (Millipore), and MsrB1
forms were visualized by immunoblot assays with MsrB1 anti-
bodies. The band corresponding to the 5-kDa protein formwas
cut from an SDS-polyacrylamide gel, and proteins were
digested with trypsin or V8 protease and subjected to
LC-MS/MS protein sequence analysis at Midwest Bio Services,
LLC.
MsrA and MsrB Activity Assays—MsrA and MsrB activities
were assayed in homogenates of the indicated mouse tissues.
200g of protein were used in each assay. The reaction (100l)
proceeded at 37 °C for 30 min in the presence of dithiothreitol
(20mM), and either 200Mdabsyl-Met-SO (MsrA assay) or 200
M dabsyl-Met-RO (MsrB assay) was added to the reaction
mixture. After stopping the reaction by adding 200 l of aceto-
nitrile, the mixtures were centrifuged at 4 °C for 15 min at
13,000 rpm, and then the supernatant (50l) was injected onto
a C18 column (ZORBAX Eclipse XDB-C18) to quantify dabsyl-
Met in an HPLC system.
Analyses of Oxidative Stress Parameters—Protein extracts
from liver, kidney, heart, testis, and brain were prepared in PBS
containing complete protease inhibitor mixture. Malondialde-
hyde was measured using the Oxiselect TBARS assay kit (Cell
Biolabs, San Diego, CA) according to the manufacturer’s
instructions. Protein carbonyl content was assayed using 2,4-
dinitrophenyl hydrazine and calculated using a molar extinc-
tion coefficient of 22 mM1 cm1 (24). Total and protein thiol
contents were measured using 5,5-dithiobis(2-nitrobenzoic
acid) as described (25) and expressed as nmol/mg protein.
Reduced and oxidized glutathione were assayed using the
Bioxytech GSH/GSSG kit (OxisResearch, Portland OR)
according to the manufacturer’s instructions.
Quantitation of Met-RO and Met-SO Residues in Proteins—
Liver samples (2mg of protein) were hydrolyzed with 3 M p-tol-
uene sulfonic acid at 110 °C for 22 h as described (26), andMet
sulfoxides were separated by HPLC after precolumn O-phtha-
laldehyde derivatization using a Zorbax C18-Rx column as
described (27).
MsrB1 Three-dimensional Structure Modeling—The three-
dimensional structure of mouse MsrB1 was modeled with
Modeler 8.2 based on sequence similarity to MsrB from Bacil-
lus subtilis (Protein Data Bank code 1XM0).
RESULTS ANDDISCUSSION
Mice Lacking MsrB1 Are Viable—To generate the MsrB1
knock-out mouse, we initially utilized a strategy wherein a Neo
cassette was inserted by homologous recombination. The
mouse MsrB1 gene is located on chromosome 17 and flanked
byRpl3l andHstst6 genes, the former being particularly close to
theMsrB1 gene (Fig. 1A). In addition, theMsrB1 gene is flanked
by a series of repetitive elements, especially abundant at the
3-end as well as in some MsrB1 introns. We employed the
targeting vector as shown in Fig. 1A, with the 3-arm either 1 or
4 kb (to avoid repetitive elements). However, no ES cells posi-
tive for homologous recombination at the MsrB1 gene were
found following repeated attempts.
We then took advantage of the genetrap clone with the dis-
rupting cassette inserted immediately after the first exon of
MsrB1 (Fig. 1B). Mice were prepared that contained this cas-
sette in both gene copies (i.e. homozygous mice) and were
found to be viable. These mice had undetectable levels of
MsrB1 mRNA (data not shown), and MsrB1 protein was also
not detected in liver, heart, kidney, testis, and lung (Fig. 1,C and
D). In addition, heterozygousmice containing the genetrap cas-
sette had lowerMsrB1 levels than wild-typemice.We further
refer to the mice lacking the MsrB1 protein and mRNA as
MsrB1 knock-out mice (MsrB1 KO). We also examined the
expression of MsrA inMsrB1 KOmice and found that it was
unchanged compared with wild-type mice. However, MsrB2
(mitochondrial MsrB) expression was slightly elevated in the
liver and heart (this protein was not detected in other tissues
examined). In contrast, MsrB3 levels in heart were not
FIGURE 1. MsrB1 knock-out mice. A, mouse MsrB1 gene and its flanking
regions. The upper part of the panel shows the MsrB1 gene and its flanking
genes, and the lower part illustrates MsrB1 exons (in red) and repetitive ele-
ments (in blue). The targeting strategy is also shown wherein a Neo cassette
(in green) replaces the first exon using the areas of homologous recombina-
tion (in gray). Two alternative 3 arms of the targeting construct are indicated
(dashed line). B, the genetrap construct. The trapping cassette was inserted
immediately downstream of the first exon. Locations of MsrB1 exons (in
orange), Sec (shown as a red U), and the Sec insertion sequence (in blue) are
also indicated. C, immunoblot analysis of MsrB1, MsrB2, andMsrA in the liver
and heart. Analyses were carried out in wild-type (/), heterozygousMsrB1
KO (/), and homozygousMsrB1 KO (/) mice. Actin was used as a load-
ing control. D, immunoblot analyses of MsrB1 andMsrA in kidney, testis, and
lung.
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changed, but it showed slightly increased levels in skeletal
muscle (both tissues are among those with highest MsrB3
expression) (Fig. S1).
A 5-kDa Selenoprotein Is an Alternative Form of MsrB1—
Since MsrB1 is a selenoprotein, we examined how its levels, as
well as the expression of other selenoproteins, were affected in
the knock-out mice.MsrB1 KO and wild-type mice were met-
abolically labeled with 75Se, and the selenoprotein expression
was examined in liver, kidney, and testis (Fig. 2A).We found no
differences in the levels of 14-kDa 75Se-labeled proteins
(which correspond in size to MsrB1). Apparently, MsrB1 over-
lapped on SDS-polyacrylamide gels with other selenoproteins
of similar size, including SelM, Sep15, SelH, and SelK. Some of
these selenoproteins were more abundant than MsrB1, which
precludedMsrB1 detectionwith 75Se. The overall expression of
selenoproteins was not changed byMsrB1KOwhen assayed by
75Se labeling (Fig. 2A) or immunoblot assays (Fig. S2).
Interesting, however, was an observation of specific removal
of a 5-kDa selenoprotein band in liver and kidney ofMsrB1KO
mice, the two tissues with highest MsrB1 expression (Fig. 2A).
To determine if the 5-kDa selenoprotein has a relation to
MsrB1,we immunoprecipitatedMsrB1 from 75Se-labeled livers
of wild-type and MsrB1 KO mice with antibodies specific for
mouse MsrB1 (Fig. 2B). The 75Se-labeled 5 kDa band was spe-
cifically removed by the MsrB1 antibodies from samples
derived fromwild-typemice, and the pooled fraction contained
both the 14- and 5-kDa protein bands, the former correspond-
ing to the full-lengthMsrB1 and the latter to the trapped 5-kDa
selenoprotein. These bands were not immunoprecipitated by
the MsrB1 antibodies from theMsrB1 KO samples.
We prepared an affinity column containing the MsrB1 anti-
bodies and used it to affinity-isolate MsrB1 forms from liver
extracts of wild-type mice. The samples were then analyzed by
immunoblot assays, and both bandswere trapped on theMsrB1
affinity column (Fig. 2C).
Next, regulation of the 5-kDa form was examined in mice
with altered Sec tRNA status (Fig. S3). Sec tRNA is essential in
mammals, but its knock-out can be rescued with wild-type or
mutant Sec tRNA transgenes. We found that expression of
wild-type Sec tRNA transgene in mice lacking the natural Sec
tRNA gene rescued expression of both 5 and 14 kDa bands as
detected by immunoblot assays with MsrB1 antibodies. How-
ever, when the Sec tRNA transgene containing a mutation in
position 37 was expressed in the Sec tRNA knock-out mice,
neither 14 nor 5 kDa bands were expressed. Thus, both MsrB1
forms were similarly regulated by Sec tRNA status.
We also found that 5- and 14-kDa forms were detected in
other mouse tissues, including lung, muscle, and spleen (Fig.
S3). When Sec tRNA knock-out was rescued with a transgene
lacking the activator region (STAF-binding site),3 expression of
both 14- and 5-kDa forms was reduced.
Overall, the data suggested that the 5-kDa selenoprotein is a
novel form of mouse MsrB1. Since Sec in MsrB1 is located in
the C-terminal portion of the protein, and the 5-kDa protein
was recognized by MsrB1 antibodies, the data suggested that
this small selenoprotein corresponded to the C-terminal por-
tion ofMsrB1. The fact that the immunoblot signal was weaker
than the 75Se signal can be explained by unequal immunogenic-
ity of the C-terminal portion and the full-lengthMsrB1. In fact,
comparison of 75Se signals for 14- and 5-kDaMsrB1 forms sug-
gests that the 5-kDa form is more abundant than the 14-kDa
form.
Mass Spectrometry Analysis of the 5-kDa MsrB1 Form—We
isolated the 5-kDa selenoprotein from mouse liver on an affin-
ity column containing MsrB1 antibodies, resolved the protein
by SDS-PAGE, and subjected the 5 kDa band to LC-MS/MS
sequence analysis. Standard trypsin digestion did not yield
MsrB1 peptides. We next used V8 protease from Staphylococ-
cus aureus, which preferentially cleaves after aspartic and glu-
tamic acid residues. This procedure detected a peptide derived
frommouseMsrB1, NGLGHEFLND (Fig. 3A). The C-terminal
part of this peptide corresponded to the expected V8 protease
cleavage site, but the N-terminal part did not. This observation
and the predicted size of the resulting MsrB1 form (5 kDa)
suggested that the identified peptide corresponded to the
N-terminal part of the short form of MsrB1.
Structural Base for Formation of the Short Form of MsrB1—
Wemodeled the three-dimensional structure of mouse MsrB1
3 B. A. Carlson and D. L. Hatfield, unpublished results.
FIGURE 2. Identification of the short form of mouse MsrB1. A, metabolic
labeling of MsrB1 KO mice with 75Se. Wild-type (/) and MsrB1 KO (/)
mice were injected with 75Se, and, after 2 days, tissues were extracted and
proteins were analyzed by SDS-PAGE, followed by PhosphorImager analysis.
Migration of full-length and short forms of MsrB1 is shown by arrows on the
left. B, immunoprecipitation of 75Se-labeled MsrB1 from mouse liver. MsrB1
was immunoprecipitated from liver extracts ofwild-type (/, left panel) and
MsrB1 KO (/, right panel) mice with MsrB1 antibodies. Initial, unbound
(flow-through), wash, and eluted fractions were collected and separated by
SDS-PAGE, and the labeledproteinbandswere visualizedwith aPhosphorIm-
ager. Migration of full-length and short forms ofMsrB1 is shown by arrows on
the left. C, MsrB1 was affinity-isolated from mouse liver extracts on the col-
umn containing MsrB1 antibodies and analyzed by immunoblot assays.
Migration of full-length and short forms of MsrB1 is shown by the arrows on
the left. Molecular weight markers are shown on the right in each panel.
MsrB1 Knock-outMouse
FEBRUARY 27, 2009•VOLUME 284•NUMBER 9 JOURNAL OF BIOLOGICAL CHEMISTRY 5989
based on theB. subtilisMsrB structure (ProteinData Bank code
1XM0) (Fig. 3B). The predicted cleavage site in MsrB1 was
located on the protein surface. Sequences located 4 amino acids
up and down the predicted cleavage site showed decreased sol-
vent exposure. Taken together, the observed size of the MsrB1
short form, the identified N-terminal peptide, and the known
occurrence of Sec in the C-terminal portion of MsrB1 all sug-
gested that the 5-kDa form was generated from the full-length
MsrB1 by proteolytic cleavage between Gly75 and Asn76.
Expression of 14- and 5-kDa MsrB1 Forms Is Regulated by
Dietary Selenium—MsrB1 is a selenoprotein, whose expression
is regulated by dietary selenium. To examine whether dietary
selenium also regulates the expression of the 5-kDa MsrB1, we
subjected wild-type mice to three Torula yeast-based selenium
diets, including selenium-deficient (i.e. no selenium added),
0.1-ppm selenium, and 0.4-ppm selenium diets. As expected,
expression of the full-length MsrB1 in the liver was dramati-
cally reduced by selenium deficiency in these mice (Fig. 4A).
Interestingly, the 5-kDa MsrB1 was undetectable under these
conditions. Thus, both 14- and 5-kDaMsrB1 forms were regu-
lated by dietary selenium.
The 5-kDa Form Is Not Due to Sample Preparation—We
examined the possibility that the 5-kDa MsrB1 is the result of
sample preparation wherein the full-length MsrB1 is degraded
by nonspecific proteolytic cleavage. Extracts from mouse liver
were incubated with or without protease inhibitors for 0, 3, 6,
and 12 h and analyzed for the occurrence of the 14- and 5-kDa
MsrB1 forms. In the presence of protease inhibitors along with
20 mM EDTA, both forms were stable for 12 h (Fig. 4B). In the
absence of inhibitors, the proteins were stable for 6 h, and
then the levels of both protein forms were reduced (rather
than converted from the 14- to 5-kDa form). Thus, both
MsrB1 forms were stable and resistant to nonspecific pro-
teolytic cleavage. This finding argues against degradation of
full-length MsrB1 during sample preparation. It should also
be noted that abundant, partially degraded forms are not
known for any selenoproteins. All major bands in the 75Se
labeling pattern can be accounted for and correspond to
FIGURE 3. The 5-kDa selenoprotein is derived from full-length mouse
MsrB1. A, protein sequence of mouse MsrB1. The identified cleavage site
between Gly75 and Asn76 in MsrB1 is shown by a caret. The detected pep-
tide derived from V8 protease cleavage is shown in blue. B, structural
model of mouse MsrB1. The zinc atomwasmodeled based on the location
of known ligands (4 cysteine residues from two CXXC motifs) of this metal
ion. Predicted protease cleavage site is marked by a red dot and high-
lighted by scissors.
FIGURE 4. Regulation of full-length and short forms of mouse MsrB1.
A, regulation by dietary selenium. Wild-type mice were fed selenium-defi-
cient (0 ppm selenium) diet and diets containing 0.1 or 0.4 ppm selenium.
Liver extracts from these mice were analyzed by Western blot assays with
antibodies against MsrB1 (upper panel). Migration of full-length and short
forms of MsrB1 is shown by arrows on the left. Each lane corresponds to liver
extract from a different mouse. The lower panel shows protein loading (Coo-
massie Blue staining). B, stability of full-length and short forms of mouse
MsrB1. Freshly prepared liver extract fromwild-typemicewas incubatedwith
or without protease inhibitor mixture for 0, 3, 6, or 12 h at room temperature,
and the two MsrB1 forms were detected by immunoblot assays.
FIGURE 5. The short form of human MsrB1. Human embryonic kidney HEK
293 cells and the HEK 293 cells subjected to MsrB1 siRNA were labeled with
75Se, protein extracts were resolved by SDS-PAGE, and the labeled proteins
were visualized with a PhosphorImager. Migration of full-length and short
forms of MsrB1 is shown by arrows on the left and molecular weight markers
on the right.
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known selenoproteins.4 In addition, the short form of MsrB1
is the only selenoprotein that did not match the size of any
predicted mouse selenoprotein.
The 5-kDa MsrB1 Form Occurs in Human Cells—To deter-
mine if the 5-kDaMsrB1 form is specific to mice or also occurs
in other species, we subjected human HEK 293 cells to meta-
bolic 75Se labeling. A 5-kDa selenoprotein band was observed
(Fig. 5, left lane). Knockdown of MsrB1 by siRNA completely
removed this band without affecting the expression of other
selenoproteins. Thus, the short form of MsrB1 also occurs in
humans. As in mice, the full-length MsrB1 overlapped with
several other selenoproteins on SDS-PAGE gel; therefore, the
effect of knockdown on this form was difficult to assess.
The molecular basis for generation of the 5-kDa MsrB1
form is not known. It is also not clear what the function of the
MsrB1 short form could be. Being part of the overall fold, the
C-terminal fragment could not catalyze the reduction of
Met-RO on its own. Further studies are required to ascertain
the mechanism by which the 5-kDa selenoprotein form is
generated and the biological function of this protein form.
Decreased MsrA Activity in MsrB1 Knock-out Mice—We
examined MsrB and MsrA activities in the liver, kidney,
heart, testis, lung, and brain ofMsrB KO mice (Fig. 6). Com-
pared with wild-type mice, total MsrB activity was most dra-
matically decreased in liver (p value 0.004) and kidneys (p
value 0.012) of MsrB1 KO mice, which are the organs with
highest MsrB1 expression. Activity was also partially
decreased in the testis (p value 0.001), lung (p value 0.002),
and brain (p value 0.0004). The least change in MsrB activity
was observed in the heart, an organ where MsrB2 is highly
expressed.
Interestingly, we also observed a decreased MsrA activity in
each of the organs tested, with liver (p value 0.009) and lung (p
value 0.002) showing the largest drop and heart the least change
in activity. A previous study revealed that MsrB activity is
decreased inMsrA KOmice (13). Thus, MsrA and MsrB1 may
regulate each other with respect to activity in the cells. It should
be noted that althoughMsrA activity was decreased (Fig. 6), its
expression was not (Fig. 1, C and D).
Oxidative Stress in MsrB1 KO Mice—We examined the
parameters of oxidative stress in MsrB1 KO mice and found
increased levels of malondialdehyde and protein carbonyls
in liver (p value 0.01), kidney (p value 0.001), and brain (p
value 0.01) samples of MsrB1 KO mice, whereas these
parameters did not change significantly in heart and testis4 S. V. Novoselov and V. N. Gladyshev, unpublished results.
FIGURE 6.MsrAandMsrB activities inMsrB1KOmice. TotalMsrB (shown in
orange) andMsrA (shown in green) activities (expressed in pmol/min/mgpro-
tein) were analyzed in extracts from the indicated tissues of wild-type mice
(/), and heterozygous (/) and homozygous (/) MsrB1 KO mice.
Dabsylated Met-RO and Met-SO substrates were used in the reaction as
described under “Experimental Procedures.”
FIGURE 7. Analyses of malondialdehyde and protein carbonyl levels in
MsrB1 KO mice. Levels of malondialdehyde (A) and protein carbonyls (B) in
liver, kidney, heart, testes, and brain of wild-type mice (/), and heterozy-
gous (/) andhomozygous (/)MsrB1KOmice are shown. Theassays are
described under “Experimental Procedures.”
MsrB1 Knock-outMouse
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(Fig. 7). We also found reduced protein and total thiol levels
in liver (p value 0.001) and kidneys (p value 0.001) of MsrB1
KO mice, but other organs were not significantly affected
(Fig. 8). Liver and kidneys were further analyzed with respect
to glutathione status. We found that the level of reduced
glutathione was decreased (p value 0.04), and GSSG
increased in these organs (p value 0.01) (Fig. 9). Accordingly,
the GSH/GSSG ratio was reduced in theMsrB1 KO samples.
Finally, we assayed for protein-based methionine sulfoxides
in liver and kidneys and found elevated levels of methionine
sulfoxide residues inMsrB1 KOmice (Fig. 10). The last find-
ing is fully consistent with the idea that MsrB1 is the main
MsrB in liver and kidneys. Overall, the data suggested an
important role of MsrB1 in the redox control in liver and
kidney, organs with maximal levels of MsrB1, but a lower
impact of this protein in other organs.
MsrB1 KO Mice Do Not Show Phenotypes Seen in MsrA KO
Mice—Previous studies revealed a dramatically reduced life
span (the mice lived only for 1 year) and a tip-toe walking
behavior ofMsrAKOmice (16). OurMsrB1KOmice appeared
to be normal (without strong phenotypes). The oldest animals,
currently 20months old, are still alive, suggesting that the same
dramatic effect on the life span found inMsrAKOmice will not
be seen with the MsrB1 KO mice. However, considering the
apparent oxidative stress seen in these mice, some reduction in
the life spanmay be expected.We also did not observe a tip-toe
walking behavior in young and middle-aged MsrB1 KO mice.
Thus, there are important differences between MsrA KO and
MsrB1 KOmice.
In summary, knock-out of theMsrB1 gene inmice is viable
and leads to the conditions of oxidative stress; however, the
phenotypes are milder than in the MsrA knock-out mice. In
addition, our analyses revealed that liver and kidney are
severely affected, whereas the redox status of other organs
examined was not changed significantly. SinceMsrB1 is also
highly expressed in liver and kidney, these organs appear to
be the prime sites of MsrB1 function. Another interesting
observation made in this study is the discovery of a novel
selenoprotein form of MsrB1, which is apparently even more
abundant than the full-length form. The short, 5-kDa form
occurs in both mice and humans and corresponds to the
C-terminal segment of the protein. Expression of this pro-
tein is regulated by dietary selenium, similar to that of the
14-kDa full-length MsrB1, and both forms appear to be sta-
FIGURE 8.Analyses of total and protein thiols inMsrB1 KOmice. The total
(A) and protein-based (B) thiols in the liver, kidney, heart, testes, and brain of
wild-type mice (/) and heterozygous (/) and homozygous (/)
MsrB1 KO mice are shown. The assays are described under “Experimental
Procedures.”
FIGURE 9. Analyses of reduced and oxidized glutathione in MsrB1 KO
mice. A, GSH, reduced glutathione. B, GSSG, oxidized glutathione. C, the ratio
of reduced/oxidized glutathione. Analyses were carried out in livers and kid-
neys of wild-type mice (/) and heterozygous (/) and homozygous
(/) MsrB1 KO mice. The assays are described under “Experimental
Procedures.”
MsrB1 Knock-outMouse
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ble proteins. Further studies will be needed to determine the
mechanism of formation and function of the 5-kDa MsrB1
form.
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FIGURE 10.Analyses ofmethionine sulfoxide in proteins. Levels ofMet-SO
andMet-RO residues in proteinsweredetermined in liver and kidney samples
from wild-type (/), and heterozygous (/) and homozygous (/)
MsrB1 KOmice. The assays are described under “Experimental Procedures.”
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